Survey: Biosimilars are Gaining Momentum Among Payers
FormularyWatch, Tasmina Hydery and Jennifer Snow
Managed care organizations are anticipating pharmacy benefit plans to include preferred biosimilars and negotiate rebates/contracts, but legal and regulatory hurdles still exist, finds a survey of 51 payers conducted by AmerisourceBergen/Xcenda. The results were presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting in Denver, Oct. 18-21, 2021.
“About 59% of those we surveyed said they agreed that biosimilars have provided their organization with meaningful savings. We have another 35% of people say they somewhat agree with that statement,” Tasmina Hydery, Pharm.D., assistant director in integrated technology solutions at AmerisouceBergen/Xcenda, said in an interview with FormularyWatch.
For the full article, visit FormularyWatch.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.